Shares of Amicus Therapeutics Inc. (NASDAQ:FOLD) were down 3.6% on Thursday . The company traded as low as $6.66 and last traded at $6.75, with a volume of 2,036,609 shares traded. The stock had previously closed at $7.00.

A number of analysts have recently weighed in on FOLD shares. Bank of America Corp. started coverage on shares of Amicus Therapeutics in a research note on Wednesday, May 18th. They issued a “buy” rating and a $10.00 price target for the company. Leerink Swann reaffirmed an “outperform” rating and issued a $17.00 price target on shares of Amicus Therapeutics in a research note on Wednesday, June 1st. Zacks Investment Research raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 price target for the company in a research note on Monday, July 25th. Finally, Chardan Capital set a $15.00 price target on shares of Amicus Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $12.19.

The firm’s market cap is $992.13 million. The company has a 50 day moving average price of $6.53 and a 200-day moving average price of $6.87.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.07. Analysts predict that Amicus Therapeutics Inc. will post ($1.35) earnings per share for the current fiscal year.

In other news, General Counsel Ellen Rosenberg acquired 15,000 shares of Amicus Therapeutics stock in a transaction that occurred on Thursday, June 2nd. The shares were acquired at an average price of $7.67 per share, with a total value of $115,050.00. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Jay Barth sold 20,916 shares of Amicus Therapeutics stock in a transaction that occurred on Wednesday, July 27th. The stock was sold at an average price of $7.00, for a total transaction of $146,412.00. Following the transaction, the insider now directly owns 25,458 shares in the company, valued at approximately $178,206. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently added to or reduced their stakes in the company. California Public Employees Retirement System raised its position in Amicus Therapeutics by 3.7% in the fourth quarter. California Public Employees Retirement System now owns 326,100 shares of the biopharmaceutical company’s stock valued at $3,163,000 after buying an additional 11,600 shares during the last quarter. RS Investment Management Co. LLC raised its position in Amicus Therapeutics by 22.0% in the fourth quarter. RS Investment Management Co. LLC now owns 3,488,863 shares of the biopharmaceutical company’s stock valued at $33,842,000 after buying an additional 628,438 shares during the last quarter. Finally, Jennison Associates LLC raised its position in Amicus Therapeutics by 3.3% in the fourth quarter. Jennison Associates LLC now owns 4,123,955 shares of the biopharmaceutical company’s stock valued at $40,002,000 after buying an additional 133,138 shares during the last quarter.

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.